Supernus Pharmaceuticals, Inc. (SUPN) Earnings History
Annual and quarterly earnings data from 2008 to 2025
Loading earnings history...
SUPN EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
SUPN Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 89.6% | -5.1% | -5.4% |
| 2024 | 88.2% | 12.3% | 11.2% |
| 2023 | 86.2% | -0.9% | 0.2% |
| 2022 | 86.9% | 6.9% | 9.1% |
| 2021 | 87.1% | 14.8% | 9.2% |
Download Data
Export SUPN earnings history in CSV or JSON format
Free sign-in required to download data
Supernus Pharmaceuticals, Inc. (SUPN) Earnings Overview
As of May 8, 2026, Supernus Pharmaceuticals, Inc. (SUPN) reported trailing twelve-month net income of -$29M, reflecting -151.5% year-over-year growth. The company earned $-0.50 per diluted share over the past four quarters, with a net profit margin of -5.4%.
Looking at the long-term picture, SUPN's historical earnings data spans multiple years. The company achieved its highest annual net income of $127M in fiscal 2020.
Supernus Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PCRX ($9M net income, 1.0% margin), ACAD ($376M net income, 36.5% margin), INVA ($504M net income, 63.8% margin), SUPN has room to improve margins relative to the peer group. Compare SUPN vs PCRX →
SUPN Earnings vs Peers
Earnings metrics vs comparable public companies
SUPN Historical Earnings Data (2008–2025)
18 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$39M | -152.2% | -$37M | $-0.68 | -5.4% | -5.1% |
| 2024 | $74M | +5512.8% | $82M | $1.32 | 11.2% | 12.3% |
| 2023 | $1M | -97.8% | -$5M | $0.02 | 0.2% | -0.9% |
| 2022 | $61M | +13.6% | $46M | $1.04 | 9.1% | 6.9% |
| 2021 | $53M | -57.9% | $86M | $0.98 | 9.2% | 14.8% |
| 2020 | $127M | +12.3% | $174M | $2.36 | 24.4% | 33.4% |
| 2019 | $113M | +1.9% | $149M | $2.10 | 28.8% | 37.8% |
| 2018 | $111M | +93.8% | $144M | $2.05 | 27.1% | 35.3% |
| 2017 | $57M | -37.2% | $100M | $1.08 | 19.0% | 32.9% |
| 2016 | $91M | +550.8% | $54M | $1.76 | 42.4% | 25.2% |
See SUPN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SUPN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SUPN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSUPN — Frequently Asked Questions
Quick answers to the most common questions about buying SUPN stock.
Is SUPN growing earnings?
SUPN EPS fell to $-0.50, with earnings declining -151.5%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-29M.
What are SUPN's profit margins?
Supernus Pharmaceuticals, Inc. net margin is -5.4%, with operating margin at -5.1%. Below-average margins reflect competitive or cost pressures.
How consistent are SUPN's earnings?
SUPN earnings data spans 2008-2025. The declining earnings trend is -151.5% YoY. Historical data enables comparison across business cycles.